BACKGROUND: Understanding the epidemiology and risk factors of adverse drug reactions (ADRs) is important in order to develop appropriate prevention strategies. This study aimed to identify risk factors associated with ADRs in hospitalised children and recommend strategies to minimise ADRs. METHODS: A prospective multicentre cohort study was conducted on paediatric general medical wards in five European and non-European hospitals. ADRs were identified by intensive chart review. Multivariable logistic regression was used to investigate risk factors associated with ADRs. For the risk factor analysis, prescribed drugs were divided into high-risk and low-risk drug groups. Analgesics, anti-epileptics, antibacterials and antimycotics for systemic use, corticosteroids for systemic use and immunosuppressant agents were considered as high-risk groups whereas the remaining drug classes were defined as low-risk drug groups. RESULTS: A total of 1,253 paediatric patients were identified [Australia (n = 145), Germany (n = 372), Hong Kong (n = 138), Malaysia (n = 291), UK (n = 307)]. A total of 328 ADRs were observed in 16.7% of patients (186/1,115). Use of five or more low-risk drugs per patient or three or more high-risk drugs was a strong predictor for ADRs (OR 4.7, 95% CI 2.4-9.3; OR 6.5, 95% CI 2.7-16.0 respectively; p < 0.001). Older children were more likely to experience ADRs; gender was not significantly associated. CONCLUSION: To reduce the risk of ADRs in children, clinicians and pharmacists should aim to minimise polypharmacy and be aware of higher ADR risks associated with some drug groups.
BACKGROUND: Understanding the epidemiology and risk factors of adverse drug reactions (ADRs) is important in order to develop appropriate prevention strategies. This study aimed to identify risk factors associated with ADRs in hospitalised children and recommend strategies to minimise ADRs. METHODS: A prospective multicentre cohort study was conducted on paediatric general medical wards in five European and non-European hospitals. ADRs were identified by intensive chart review. Multivariable logistic regression was used to investigate risk factors associated with ADRs. For the risk factor analysis, prescribed drugs were divided into high-risk and low-risk drug groups. Analgesics, anti-epileptics, antibacterials and antimycotics for systemic use, corticosteroids for systemic use and immunosuppressant agents were considered as high-risk groups whereas the remaining drug classes were defined as low-risk drug groups. RESULTS: A total of 1,253 paediatric patients were identified [Australia (n = 145), Germany (n = 372), Hong Kong (n = 138), Malaysia (n = 291), UK (n = 307)]. A total of 328 ADRs were observed in 16.7% of patients (186/1,115). Use of five or more low-risk drugs per patient or three or more high-risk drugs was a strong predictor for ADRs (OR 4.7, 95% CI 2.4-9.3; OR 6.5, 95% CI 2.7-16.0 respectively; p < 0.001). Older children were more likely to experience ADRs; gender was not significantly associated. CONCLUSION: To reduce the risk of ADRs in children, clinicians and pharmacists should aim to minimise polypharmacy and be aware of higher ADR risks associated with some drug groups.
Authors: Asia N Rashed; Ian C K Wong; Noel Cranswick; Barbara Hefele; Stephen Tomlin; John Jackman; Kenneth Lee; Kam-Lun E Hon; Jeffrey Ong; Maisoon Ghaleb; Siew Siang Chua; Tea Ming Hui; Wolfgang Rascher; Antje Neubert Journal: Drug Saf Date: 2012-06-01 Impact factor: 5.606
Authors: Petra A Thuermann; Roland Windecker; Joachim Steffen; Markus Schaefer; Ute Tenter; Erich Reese; Hermann Menger; Klaus Schmitt Journal: Drug Saf Date: 2002 Impact factor: 5.606
Authors: S Major; S Badr; L Bahlawan; G Hassan; T Khogaoghlanian; R Khalil; A Melhem; R Richani; F Younes; J Yeretzian; M Khogali; R Sabra Journal: Clin Pharmacol Ther Date: 1998-10 Impact factor: 6.875
Authors: Y Zopf; C Rabe; A Neubert; K G Gassmann; W Rascher; E G Hahn; K Brune; H Dormann Journal: Eur J Clin Pharmacol Date: 2008-07-05 Impact factor: 2.953
Authors: Cornelis S van der Hooft; Jeanne P Dieleman; Claire Siemes; Albert-Jan L H J Aarnoudse; Katia M C Verhamme; Bruno H C H Stricker; Miriam C J M Sturkenboom Journal: Pharmacoepidemiol Drug Saf Date: 2008-04 Impact factor: 2.890
Authors: Emma C Davies; Christopher F Green; Stephen Taylor; Paula R Williamson; David R Mottram; Munir Pirmohamed Journal: PLoS One Date: 2009-02-11 Impact factor: 3.240
Authors: Asia N Rashed; Antje Neubert; Stephen Tomlin; John Jackman; Hani Alhamdan; Adnan AlShaikh; Ahmed Attar; Mohammed Aseeri; Lynda Wilton; Ian C K Wong Journal: Eur J Clin Pharmacol Date: 2012-05-30 Impact factor: 2.953
Authors: Paulo Henrique Santos Andrade; Adriano da Silva Santos; Carlos Adriano Santos Souza; Iza Maria Fraga Lobo; Wellington Barros da Silva Journal: Ther Adv Drug Saf Date: 2017-04-25
Authors: Asia N Rashed; Lynda Wilton; Charles C H Lo; Benjamin Y S Kwong; Suzanne Leung; Ian C K Wong Journal: Br J Clin Pharmacol Date: 2014-05 Impact factor: 4.335
Authors: Asia N Rashed; Antje Neubert; Hani Alhamdan; Stephen Tomlin; Aeshah Alazmi; Adnan AlShaikh; Lynda Wilton; Ian C K Wong Journal: Int J Clin Pharm Date: 2013-04-03